All articles by Jennifer Smith-Parker
Jennifer C. Smith is an award-winning healthcare editor with 15+ years of expertise in the US and European pharmaceutical, regulatory and pricing/reimbursement sector. She carries in-depth knowledge on the clinical trials landscape and concerns that affect the pharma and biotech industry. She has moderated a number of conferences over the years, and led panel discussions on a wide-ranging set of topics. She has honed her skillet on the intersection of online journalism and business acumen, with a good understanding of SEO concepts and readership analytics to drive content strategy.
Jennifer Smith-Parker
Remote clinical trial monitoring uptake rises but validation questions swirl
DCT Adoption Tracker: Clinical Trials Arena reviews the burgeoning trend on remote monitoring and look into regulatory know-how needed to ensure success.
ESG in clinical trials: what pharma needs to know
AI is main investment target, while 3D printing remains a largely untapped area.
LoA Update: TG’s Phase III ublituximab for relapsing multiple sclerosis sees 10-point boost to FDA regulatory potential
As of 21 December, the likelihood of approval (LoA) for TG Therapeutics’ Phase III anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS) in the US rose 10 points, according to GlobalData’s LoA data.
LoA Update: BeiGene’s Phase III tislelizumab for esophageal squamous cell carcinoma sees 10-point jump for FDA approval forecast
As of 29 January, the US likelihood of approval (LoA) for BeiGene’s Phase III anti-PD-1 antibody for esophageal squamous cell carcinoma (ESCC) rose 10 points, according to GlobalData’s LoA data.
LoA Update: Agios’ Phase III mitapivat sulphate for pyruvate kinase deficiency sees 12-point rise in US approval prospects
As of 28 January, the likelihood of approval (LoA) by the FDA for Agios Pharmaceuticals’ Phase III drug for pyruvate kinase (PK) deficiency increased 12 points, according to GlobalData’s LoA data.
